Assembly Biosciences Profit Margin

The latest profit margin for ASMB is -21.54% as of March 2026. That compares with -175.58% in the prior-year period — up 87.7% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Assembly Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, ASMB's profit margin moved from -175.58% to -21.54% — a 87.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Assembly Biosciences's valuation or profitability profile.

Against Healthcare companies, ASMB currently prints -21.54% for profit margin, while the sector average sits near 15.58%. That is roughly 238.2% below the sector mean. Large gaps often invite a closer look at Assembly Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Assembly Biosciences converts resources into returns. At -21.54%, ASMB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -175.58% in the prior-year period — up 87.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ASMB's profit margin (-21.54%), review year-over-year change from -175.58%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.